Sustained Release of Antivirals for Treatment or Prevention of HIV (SRATP) (R01 Clinical Trial Not Allowed)

End Date: 
Jan 07 2022
Grant Type: 
Grant Source: 

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate the high-risk research needed to develop new and innovative sustained release antiviral strategies for treatment of HIV disease or the prevention of HIV transmission and acquisition. Adherence to dosing regimens is a shared critical issue for both HIV treatment and prevention. It has been hypothesized that development of approaches eliminating or reducing the impact of individual adherence could increase the efficacy of treatment strategies and provide for prevention of HIV transmission. Although initial development of sustained release methods for prevention and treatment has begun, the effort is limited in scope and is not taking full advantage of available antivirals and the range of new and novel formulation approaches to achieve sustained release of drugs. (PAR-20-029)

This grant has 3 application due dates: January 7, 2020; January 7, 2021; January 7, 2022